MiNK Therapeutics, Inc. Common Stock

INKTNASDAQ • USD
9.48 USD
↗ 0.13 (1.39%)🟢LIVE (AS OF 11:53 AM EST)
🟢Market: OPEN

MiNK Therapeutics, Inc. Common Stock (INKT) trades at $9.48 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (67.8%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, INKT trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 16, 2026.

Open?$9.24
High?$9.70
Low?$9.24
Prev. Close?$9.35
Volume?12.2K
Avg. Volume?12.9K
VWAP?$9.56
Rel. Volume?0.94x
Bid / Ask
Bid?$7.95 × 100
Ask?$11.20 × 100
Spread?$3.25
Midpoint?$9.58
Valuation & Ratios
Market Cap?48.0M
Shares Out?5.1M
Float?2.0M
Float %?39.2%
P/E Ratio?N/A
P/B Ratio?-2.95
EPS?-$2.15
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Employees
15
Market Cap
48.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-10-15
Address
149 FIFTH AVENUE
NEW YORK, NY 10010
Phone: 212-994-8250
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
48
Piotroski F-Score?0/9Weak
Altman Z-Score?-31.46Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.76%Low
Short Interest?55.1K
Days to Cover?4.3
Free Float2.0M
Avg Daily Volume12.9K
Settlement Date2026-10-30
Financial Health
Current Ratio?0.97Weak
Quick Ratio?0.97Weak
Cash Ratio?0.91Adequate
Debt/Equity?-0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-2.95CHEAP▾
P/S?
Peers
100
S&P
3
240.00HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
202.64HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
94
67.8%STRONG▾
ROA?
S&P
3
-133.8%WEAK▾
Cash Flow & Enterprise
FCF?$-7221478
Enterprise Value?$40.5M
Fundamentals ratios updated end of day